Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lessons Learned: How Avandia is Changing the Way FDA Does Business

Feb 01 2011

• By Kate Rawson

Related Content

Regulating in Real Time: Avandia and the Challenges of Making "Sound Decisions" Under Heavy Scrutiny

Nov 01 2010

A Tale of Two Drugs: Meridia and Avandia, and the Issues that Separated Them

Nov 01 2010

How FDA Withdraws A Drug

Oct 01 2010

Communication Conundrum: Is Early Drug Safety Disclosure Better?

Oct 01 2008

Regulatory Risk and Business Development: Type 2 Diabetes Falls Out of Favor

Oct 01 2008

FDA Releases Report on Transparency to Regulated Industry: Not Much To See Here

Feb 01 2011

Fostering Trust at FDA

Feb 01 2011

The Unsung Vytorin Victim: Primary-Care Marketing

Feb 01 2008

Related Companies

GSK plc

Eli Lilly and Company

Abbott

Additional Topics

Regulation BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window